
Publication|Articles|February 12, 2024
Peers & Perspectives in Oncology
- February I, 2024
- Volume 2
- Issue 2
- Pages: 58
Roundtable Roundup: February | Biliary Tract Cancer
Author(s)Targeted Oncology Staff
In separate virtual live events, R. Kate Kelley, MD, with Daneng Li, MD, and Chih-Yi (Andy) Liao, MD, with Anjana Pillai, MD, discussed imaging and treatment for a patient with biliary tract cancer with event participants.
Advertisement
CASE SUMMARY
- A 72-year-old man presented to a local hospital with a 4-month history of jaundice, dark urine, itchy skin, and unintentional weight loss of 8 lb.
- He was referred to a gastrointestinal specialist 2 months ago by his primary care physician but had no resolution of symptoms.
- Physical examination showed an obese, tired-appearing man.
- His medical history was unremarkable aside from a 20 pack-year history of smoking and relatively heavy alcohol consumption at approximately 15 drinks per week.
- His laboratory results showed the following: Total bilirubin: 22.9 mg/dL
- Direct bilirubin: 19.2 mg/dL
- Alkaline phosphatase: 89 U/L
- Alanine aminotransferase: 89 U/L
- Aspartate aminotransferase: 99 U/L
- γ-glutamyl transpeptidase: 222 U/L
- Cancer antigen 19-9: 293 U/mL
- Carcinoembryonic antigen: 10 ng/mL
- α-fetoprotein: 20 ng/mL
- Hepatitis B screening and autoimmune profile were negative.
CASE UPDATE
- The patient underwent endoscopic retrograde cholangiopancreatography with brush cytology.
- Bile duct strictures were visualized during the procedure.
- Pathologic diagnosis:
- Atypical tumor cells with enlarged nuclei and prominent nucleoli
- Abundant stromal component with a desmoplastic reaction
- Moderately differentiated infiltrative glands arising from a biliary intraepithelial neoplasia at the site of the choledocus, consistent with extrahepatic cholangiocarcinoma
- Three weeks after surgery:
- Total bilirubin: 1.2 mg/dL
- Direct bilirubin: 0.2 mg/dL
- A CT scan demonstrated multiple liver lesions plus extrahepatic perihilar regional lymph nodes and lesions in the left lung and left femur.
Articles in this issue
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5







































